Evaluation of the Effect of Narrow band Ultraviolet B Versus Methotrexate on Serum Chitotriosidase Level in Psoriasis | ||||
Aswan University Medical Journal | ||||
Articles in Press, Accepted Manuscript, Available Online from 17 January 2025 | ||||
Document Type: Original Article | ||||
DOI: 10.21608/aumj.2025.339597.1163 | ||||
![]() | ||||
Authors | ||||
Ali Mohamed Younis1; Shimaa Ali Hussien ![]() | ||||
1Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Aswan University | ||||
2Department of Dermatology, Venereology and Andrology, Faculty of Medicine, South Valley University | ||||
Abstract | ||||
Background: Psoriasis is a common, chronic Papulosquamous inflammatory skin disease with an incidence of approximately 2% worldwide. Aim: assess serum level of Chitotriosidase (CHIIT1) in patients with psoriasis and its relationship with psoriasis area and severity index (PASI) score before and after treatment with narrow-band ultraviolet B (NB-UVB) phototherapy and Methotrexate (MTX). Materials and methods: This study was a randomized clinical study included 30 patients with psoriasis vulgaris, ranging in age from 10 to 60 years, who were divided randomly into two groups, group A including 15 patients received NB-UVB treatment and group B received MTX in addition to 15 healthy individuals as a control group, with the same age and sex groups as patients of psoriasis vulgaris. Results: The serum level of CHIIT1 shows a statistically significant difference between the three groups; the highest mean CHIIT1 level was in the MTX group (830.2 ± 99.7) compared with both the NB-UVB group (534.2 ± 27.9) and the control group (18.86 ± 2.7). Conclusion: CHIIT1 levels in psoriasis are substantially higher than in controls. CHIIT1 level were dramatically reduced during NB-UVB and MTX treatment. CHIIT1 level may serve as a potential biomarker in psoriasis diagnosis and prognosis. | ||||
Keywords | ||||
Psoriasis; Chitotriosidase; NB-UVB; Methotrexate | ||||
Statistics Article View: 81 |
||||